Short‐Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients
ABSTRACT This research endeavored to ascertain whether four cycles of oxaliplatin in conjunction with standard radiation (oxaliplatin‐CRT) could enhance overall survival when compared with standard neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC). A Phase III randomized...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70222 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849235256810405888 |
|---|---|
| author | Rongxin Zhang Fulong Wang Xinhua Jiang Hao Wang Weili Zhang Zhifan Zeng Yuanhong Gao Xiaojun Wu Gong Chen Liren Li Peirong Ding Shixun Lu Jian Zhang Min Liu Qiaoxuan Wang Weiwei Xiao Zhizhong Pan Desen Wan Zhen‐hai Lu |
| author_facet | Rongxin Zhang Fulong Wang Xinhua Jiang Hao Wang Weili Zhang Zhifan Zeng Yuanhong Gao Xiaojun Wu Gong Chen Liren Li Peirong Ding Shixun Lu Jian Zhang Min Liu Qiaoxuan Wang Weiwei Xiao Zhizhong Pan Desen Wan Zhen‐hai Lu |
| author_sort | Rongxin Zhang |
| collection | DOAJ |
| description | ABSTRACT This research endeavored to ascertain whether four cycles of oxaliplatin in conjunction with standard radiation (oxaliplatin‐CRT) could enhance overall survival when compared with standard neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC). A Phase III randomized trial (SONCAR Trial, NCT02031939) was conducted in China, involving patients diagnosed with clinical T3‐4 and/or N+ rectal cancer. Patients were randomly allocated to the experimental arm (receiving pelvic radiation (50 Gy/25 fractions) in conjunction with oxaliplatin and capecitabine) or the control arm (pelvic radiation in conjunction with capecitabine alone). The main endpoint was a 5‐year OS, while the secondary objectives encompassed pathological complete response (pCR), 3‐year disease‐free survival, and surgical complications. A total of 536 patients were assessable. The rate of pCR was notably higher in the experimental group (31.9%) than in the control group (21.5%) (p = 0.008). The clinical complete response (cCR) rate was also higher in the experimental group (p = 0.024). Among patients with tumors located within 5 cm of the anal verge, the experimental group exhibited a significantly greater tumor regression, with rates of 33.8% compared to 21.6% in the control group (p = 0.024). In summary, oxaliplatin‐CRT significantly augmented the tumor response in LARC patients with manageable toxicity. |
| format | Article |
| id | doaj-art-dc0ecdbdf628495b82a690d90bafe4cb |
| institution | Kabale University |
| issn | 2688-2663 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj-art-dc0ecdbdf628495b82a690d90bafe4cb2025-08-20T04:02:50ZengWileyMedComm2688-26632025-08-0168n/an/a10.1002/mco2.70222Short‐Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer PatientsRongxin Zhang0Fulong Wang1Xinhua Jiang2Hao Wang3Weili Zhang4Zhifan Zeng5Yuanhong Gao6Xiaojun Wu7Gong Chen8Liren Li9Peirong Ding10Shixun Lu11Jian Zhang12Min Liu13Qiaoxuan Wang14Weiwei Xiao15Zhizhong Pan16Desen Wan17Zhen‐hai Lu18Department of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaState Key Laboratory of Oncology in South ChinaGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaState Key Laboratory of Oncology in South ChinaGuangzhouGuangdongChinaState Key Laboratory of Oncology in South ChinaGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaState Key Laboratory of Oncology in South ChinaGuangzhouGuangdongChinaState Key Laboratory of OphthalmologyZhongshan Ophthalmic CenterSun Yat‐sen UniversityGuangzhouGuangdongChinaState Key Laboratory of Oncology in South ChinaGuangzhouGuangdongChinaState Key Laboratory of Oncology in South ChinaGuangzhouGuangdongChinaState Key Laboratory of Oncology in South ChinaGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaDepartment of Colorectal SurgerySun Yat‐sen University Cancer CenterGuangzhouGuangdongChinaABSTRACT This research endeavored to ascertain whether four cycles of oxaliplatin in conjunction with standard radiation (oxaliplatin‐CRT) could enhance overall survival when compared with standard neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC). A Phase III randomized trial (SONCAR Trial, NCT02031939) was conducted in China, involving patients diagnosed with clinical T3‐4 and/or N+ rectal cancer. Patients were randomly allocated to the experimental arm (receiving pelvic radiation (50 Gy/25 fractions) in conjunction with oxaliplatin and capecitabine) or the control arm (pelvic radiation in conjunction with capecitabine alone). The main endpoint was a 5‐year OS, while the secondary objectives encompassed pathological complete response (pCR), 3‐year disease‐free survival, and surgical complications. A total of 536 patients were assessable. The rate of pCR was notably higher in the experimental group (31.9%) than in the control group (21.5%) (p = 0.008). The clinical complete response (cCR) rate was also higher in the experimental group (p = 0.024). Among patients with tumors located within 5 cm of the anal verge, the experimental group exhibited a significantly greater tumor regression, with rates of 33.8% compared to 21.6% in the control group (p = 0.024). In summary, oxaliplatin‐CRT significantly augmented the tumor response in LARC patients with manageable toxicity.https://doi.org/10.1002/mco2.70222locally advanced rectal cancerneoadjuvant chemoradiotherapyoxaliplatintoxicity |
| spellingShingle | Rongxin Zhang Fulong Wang Xinhua Jiang Hao Wang Weili Zhang Zhifan Zeng Yuanhong Gao Xiaojun Wu Gong Chen Liren Li Peirong Ding Shixun Lu Jian Zhang Min Liu Qiaoxuan Wang Weiwei Xiao Zhizhong Pan Desen Wan Zhen‐hai Lu Short‐Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients MedComm locally advanced rectal cancer neoadjuvant chemoradiotherapy oxaliplatin toxicity |
| title | Short‐Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients |
| title_full | Short‐Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients |
| title_fullStr | Short‐Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients |
| title_full_unstemmed | Short‐Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients |
| title_short | Short‐Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients |
| title_sort | short term results of the soncar study optimized neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients |
| topic | locally advanced rectal cancer neoadjuvant chemoradiotherapy oxaliplatin toxicity |
| url | https://doi.org/10.1002/mco2.70222 |
| work_keys_str_mv | AT rongxinzhang shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT fulongwang shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT xinhuajiang shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT haowang shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT weilizhang shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT zhifanzeng shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT yuanhonggao shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT xiaojunwu shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT gongchen shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT lirenli shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT peirongding shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT shixunlu shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT jianzhang shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT minliu shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT qiaoxuanwang shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT weiweixiao shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT zhizhongpan shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT desenwan shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients AT zhenhailu shorttermresultsofthesoncarstudyoptimizedneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancerpatients |